2015 News Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
03/19/15Verastem to Present Data at the 2015 American Association of Cancer Research Annual Meeting
BOSTON--(BUSINESS WIRE)--Mar. 19, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced data presentations at the 2015 American Association of Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA. The details for the data presentations at AACR are as follows: ... 
Printer Friendly Version
03/10/15Verastem Reports Year-End 2014 Financial Results
— COMMAND Interim Analysis Expected Second Quarter 2015 — BOSTON--(BUSINESS WIRE)--Mar. 10, 2015-- Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the year ended December 31, 2014, and also commented on corporate accomplishments and plans. "COMMAND enrollment remains on track and we continue to anticipate condu... 
Printer Friendly Version
03/03/15Verastem to Present at 27th Annual ROTH Conference
BOSTON--(BUSINESS WIRE)--Mar. 3, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the 27th Annual ROTH Conference on Monday, March 9 at 3:30 p.m. PT at the Ritz-Carlton in Dana Point, CA. A live webcast of the presentation will be available on the company's website at www.verastem.com. An arc... 
Printer Friendly Version
02/12/15Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma
BOSTON--(BUSINESS WIRE)--Feb. 12, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from ... 
Printer Friendly Version
02/05/15Verastem Announces the Grant of Inducement Awards
BOSTON--(BUSINESS WIRE)--Feb. 5, 2015-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that on February 2, 2015, the Company granted stock options to seven new employees to purchase an aggregate of 210,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Verastem pursuant to N... 
Printer Friendly Version
02/03/15Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Feb. 3, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the following upcoming investor conferences: 17th Annual BIO CEO & Investor Conference on Tuesday, February 10 at 1:30 p.m. ET at the Waldorf Astoria Hotel in New York City Le... 
Printer Friendly Version
01/29/15Verastem Announces Closing of $54 Million Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
BOSTON--(BUSINESS WIRE)--Jan. 29, 2015-- Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares of common stock, at the public offering price of $6.50 per share. The exercise o... 
Printer Friendly Version
01/22/15Verastem Announces Pricing of Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Jan. 22, 2015-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock, offered at a price of $6.50 per share to the public. The net proceeds to Verastem from this offering are expected to be approximately $44.1 million, after... 
Printer Friendly Version
01/20/15Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
BOSTON--(BUSINESS WIRE)--Jan. 20, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. ... 
Printer Friendly Version
01/20/15Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma
-Study Builds Upon Encouraging Clinical Progress for Both VS-6063 and VS-5584- -Synergistic Activity of VS-6063 and VS-5584 Demonstrated in Preclinical Models of Mesothelioma- BOSTON--(BUSINESS WIRE)--Jan. 20, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced dosing of the first patient in a new clinical trial evaluating ... 
Printer Friendly Version
01/20/15Verastem Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Jan. 20, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it intends to offer and sell $40 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size... 
Printer Friendly Version
01/16/15Verastem Announces Publication of Scientific Data for VS-5584 in Cancer Research
BOSTON--(BUSINESS WIRE)--Jan. 16, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a paper, titled “PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells,” has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research (AACR). The paper discusses results from ... 
Printer Friendly Version
01/08/15Verastem Provides Year-End 2014 Update and Outlook for 2015
-COMMAND Study Currently On Track for Completion of Enrollment by Year-End 2015- -Signals of Clinical Activity in all Programs Targeting Cancer Stem Cells Have Been Observed- -Management to Host Conference Call Today at 4:30 PM ET- -(877) 341-5660 (U.S. and Canada) or (315) 625-3226 (international). Passcode: 60568979. To access the live slide presentation: http://bit.ly/1vYH8yN- BOSTON--(BUSINESS WIRE)--Jan. 8,... 
Printer Friendly Version
01/05/15Verastem to Host Conference Call and Slide Webcast on Thursday, January 8 at 4:30pm ET
-Management to Provide 2014 Year-End Update and 2015 Outlook- BOSTON--(BUSINESS WIRE)--Jan. 5, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the Company will host a conference call and slide webcast on Thursday, January 8, 2015 at 4:30 p.m. Eastern Time to review the company’s progress in 2014 and discuss upcoming milestones for 2015.... 
Printer Friendly Version